Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC drops offense on Defense

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission decides not to pursue investigations into health claims substantiation for Prestige Brands' Chloraseptic Defense Daily Health Strips and Insight Pharmaceuticals' Sucrets Defense lozenges in part because both products have been permanently discontinued, FTC states in June 1 letters to the companies. The Chloraseptic Defense strips claimed to boost the immune system and prevent flu and cold. Similarly, Sucrets Defense claimed to boost the immune system and fight colds as well as provide protection before entering crowded places. Other factors leading to FTC's decisions to not pursue the investigations include the short periods of time the products were marketed, the limited nature of the products' ad campaigns and relatively small resulting sales, FTC states...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel